Implantable Direct-Current Bone Stimulators in High-Risk and Revision Foot and Ankle Surgery: A Retrospective Analysis With Outcome Assessment
Johnny T. C. Lau, MD, Emmanouil D. Stamatis, MD, Mark S. Myerson, MD, and Lew C. Schon, MD
Dr. Lau is Fellow, Dr. Stamatis is Fellow, Dr. Myerson is Attending, and Dr. Schon is Attending, Department of Orthopaedic Surgery, Union Memorial Hospital, Baltimore, Maryland.
Efficacy and morbidity of a surgically implanted direct-current bone stimulator were evaluated in 38 patients (40 feet) with fracture nonunion or at high risk for nonunion; 14 of these patients had Charcot (diabetic) neuroarthropathy. Union occurred in 26 (65%) of the 40 feet; complications other than nonunion occurred in 16 feet (40%). Two amputations (5%) were performed in cases of intractable neuritis and deep infection. Of the 6 cases of deep infection (15%), 5 resolved with device removal, and the sixth case required below-knee amputation. Use of a bone stimulator in patients with diabetes may be problematic, but the device did not have any adverse effects in other high-risk patients.